SARA LEMMON: Open Payments
NPI 1942672647 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,825 in 143 payments from 17 companies in 2025. Trend: 2023 $672 · 2024 $1,741 · 2025 $2,825
Food & beverage: $2,825
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $375 |
| Vanda Pharmaceuticals Inc. | 17 | $367 |
| Otsuka America Pharmaceutical, Inc. | 14 | $289 |
| Axsome Therapeutics, Inc. | 10 | $267 |
| Neurocrine BioSciences, Inc. | 11 | $224 |
| Alkermes, Inc. | 11 | $196 |
| Lundbeck LLC | 9 | $187 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $155 |
| Indivior Inc. | 6 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $136 |
Products named: REXULTI, VRAYLAR, HETLIOZ, Auvelity, INGREZZA, CAPLYTA, SUBLOCADE, TRINTELLIX.
Industry payments across MD — which companies pay providers there.
